 Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43 YOY. Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands their customers, solves their pain points, and has earned their trust. This is a deep moat. 